Benign Prostatic Hyperplasia Treatment Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)

Benign Prostatic Hyperplasia Treatment Market Size

BPH Treatment Market Trends & Growth Drivers

Technological Advancements Are Biggest Market Trends

• Technology has played a crucial part in most recent advancements in BPH management, no more so than in the rise of procedures that do not necessitate general anesthesia or prolonged hospital stays.
• There is a novel mechanical implant available for the prostate that moves the prostate's invading lobes out of the way, to enhance urine flow.
• Moreover, the UroLift device has shown to cause minimal disruption to ejaculation and, when compared to the traditional surgery, known as TURP, in a recent trial, had similar outcomes, including patient satisfaction with minimal complications.
• Moreover, prostatic artery embolization is a new technique that is performed by an interventional radiologist. Performed under a local anesthetic, it involves a groin artery puncture with the super-selective vascular embolization of the arteries to the prostate.
• This is postulated to cause a shrinkage of the prostate and an improvement in urinary function.
• Additionally, a promising technique, prostate ablation using hydrodissection uses a high-speed, robot-assisted, image-guided saline jet, requiring no electrical current or high temperatures.
• It helps achieve greater accuracy in the target tissue, minimizes bleeding, and has indirect effects on pertinent nearby structures, such as the prostatic capsule, bladder neck, and external sphincter, with the possibility of maintaining ejaculatory function.
• Another promising method is prostate hydration, which uses the convective energy transfer capabilities (better than conductive techniques) of steam over the defined area of the prostatic tissue (transition zone), reaching temperatures of 70–80 °C and causing instantaneous cell death in the target tissue.
• A needle is introduced into each prostate lobe individually, as many times as required, to completely round the prostate mass.
• The treatment is carried out via cystoscopy.
• For around nine seconds, vapor steam is discharged circumferentially at a 120-degree angle to the tip of the needle.

Surging Awareness of BPH Disorder Fuels Market Growth

• In most men, BPH worsens with age. It can lead to bladder damage and infection, cause blood in the urine, and result in kidney damage.
• For its prevention, various programs and campaigns are run globally. For instance, in North America, every year, September is observed as National Prostate Health Month by health experts, health advocates, and individuals concerned with prostate health.
• The main purpose of designating a whole month for this body part is to create awareness of the risk factors and symptoms of the related diseases.
• In the same way, in Greece, the Hellenic Urological Association (HUA) organizes a week-long public awareness campaign on prostate gland diseases in September, under the motto "don't ignore your prostate”, within the framework of the European Week of Urological Diseases.
• Moreover, within the framework of the Prostate Disease Week, the HUA implements a series of actions, with the support of Astellas, which include media interviews, distribution of prostate gland leaflets, and events in various cities of Greece.
• Interested parties can visit public hospitals during the hours of operation of their outpatient clinics and be examined.

Side-Effects of BPH Medication Hamper Market Growth

• α1-blockers are now the most-popular type of medication that urologists prescribe to treat benign prostatic hyperplasia, and they can produce observable benefits in LUTS patients.
• However, cardiovascular problems, such as postural hypotension, asthenia, and light-headedness, are linked to α1-blockers.
• The drop in the blood pressure brought on by α1-blocker-induced vasodilatation in smooth muscle cells and endothelial cells may be the mechanism driving these adverse cardiovascular effects.
• The central nervous system, which is known to express α1- adrenoceptors, is also connected to these issues.
• These negative effects can be brought on by almost all α1-blockers, especially terazosin and doxazosin.
• Selective α1-blockers only slightly increase the risk of these side-effects.
• Additionally, benign prostatic hyperplasia treatment results in ejaculatory dysfunction. It is well known that α1-blockers induce retrograde ejaculation.
• Tamsulosin and silodosin have the strongest correlation with retrograde ejaculation, according to several meta-analyses; other α1-blockers, including alfuzosin, doxazosin, and terazosin, have a much smaller effect on ejaculatory function.
• Moreover, intraoperative floppy iris syndrome (IFIS) is linked to benign prostatic hyperplasia treatment. Patients who undergo cataract surgery while taking α-blockers frequently experience this adverse effect; however, the risk of IFIS is minimal.
• The majority of the α1-blockers are said to be capable of causing IFIS, and tamsulosin is the one with the highest risk, thereby constraining the growth of the market to some extent.

BPH Treatment Market Analysis

Type Analysis

The larger benign prostatic hyperplasia treatment market share, of 85%, is held by drugs in 2024, and this bifurcation will also grow faster in the future. This is attributed to the burgeoning demand for alpha-blockers as these medications relax the muscle of the prostate and bladder neck, which enables urine to flow more easily. Among the different types of drugs, alpha-blockers have been widely utilized to treat the disease in recent years. Their increasing use and the abundance of medications under development present potential opportunities for the industry.

Additionally, due to the high demand for alpha-blockers, businesses such as Sun Pharmaceutical Industries Ltd. and Astellas Pharma Inc. continue to invest in this industry. The development of such medication, which may be used in both monotherapy and combination therapy, is driving their demand. They are a preferred medication for the treatment of benign prostatic hyperplasia since they are rather effective and inexpensive.

The types analyzed are mentioned below:

• Drug Treatment (Larger and Faster-Growing Category)
  • Alpha blockers
    • Alfuzosin
    • Doxazosin
    • Tamsulosin
    • Silodosin
    • Other alpha blockers
  • 5-alpha reductase inhibitors
    • Finasteride
    • Dutasteride
• Surgical Treatment
  • TURP
  • TUMT
  • TUNA
  • Laser therapy
  • Prostatic stenting
  • UroLift therapy
  • Rezûm therapy

End User Analysis

Home healthcare settings account for the larger share in the market in 2024, and they are expected to record the higher CAGR, of 6%, during the forecast period, due to the increasing number of patients prescribed drugs over surgical treatment. Moreover, a significant proportion of the population prefers drug-based treatment at their homes over treatment in hospitals. Further, patients are highly recommended to take medications for a couple of months after surgeries, which further bolsters the market expansion in this category.

The following end users are covered:

• Home Healthcare (Larger and Faster-Growing Category)
• Hospitals & Clinics

Regional Analysis

In 2024, North America accounts for the largest share, of 40%, in the BPH treatment market. The growing incidence of the problem is fueling the adoption of advanced treatments, such as laser therapy, prostatic stenting, and UroLift therapy, thereby driving the industry development in the region. Further, the favorable reimbursement policies and a rising number of trained surgeons will support the advance of the players in the region in the next few years.

The region has the presence of several device and drug manufacturers, who are strongly focused on conducting R&D activities and product innovations to enhance the quality of care. Additionally, there is high penetration of laser therapy owing to the availability of advanced healthcare infrastructure. Several clinics and urology centers are equipped with modern laser equipment to treat BPH, which, in turn, boosts the regional progress.

The APAC region is expected to witness the fastest growth during the forecast period, at a CAGR of 6.5%. The surging living standards, flourishing per capita income and spending capability, increasing urological disease burden, and rising investment in the healthcare sector inflate the progress.

Moreover, the burgeoning aging male population in the region, coupled with an escalation in the incidence of diabetes and obesity, is expected to drive the prevalence of BPH and other lower urinary tract conditions. China, Japan, and India together have a large elderly male population, which requires regular medical assistance, as it is highly susceptible to chronic diseases owing to its low immunity. Thus, patients with an irregular growth of the prostate are required to be treated, to prevent urethra blockage and reduce the associated cancer risk.

For instance, the prevalent cases and incident cases of BPH in China were approximately 20.34 million and 2.84 million, respectively, and the standardized incidence rate and standardized prevalence rate were 280.64/100,000 and 2,220.85/100,000, respectively, in 2019. Similarly, in India, it is an ordinary elderly problem, with an incidence of 93.3%, which fosters the demand for drugs as well as surgical treatments.

We studied the following regions and countries:

• North America (Largest Regional Market)
  • U.S. (Larger and Faster-Growing Country Market)
  • Canada
• Europe
  • Germany (Largest Country Market)
  • France
  • U.K. (Fastest-Growing Country Market)
  • Rest of Europe
• Asia-Pacific (APAC) (Faster-Growing Regional Market)
  • China (Largest and Fastest-Growing Country Market)
  • Japan
  • India
  • South Korea
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest and Fastest-Growing Country Market)
  • Mexico
  • Rest of LATAM
• Middle East and Africa (MEA)
  • South Africa (Largest and Fastest-Growing Country Market)
  • Saudi Arabia
  • Rest of MEA

BPH Treatment Market Share

• The BPH treatment market is fragmented as there are two main kinds of therapies for this condition: drugs and surgery.
• Even then, different drugs and types of devices and procedures are used worldwide, which restrains any one company from holding a clear edge.
• Pharma companies generally offer drugs only; likewise, medical device companies hold sway in surgical devices.
• Further, regulatory guidelines across regions, allowing a variety of players to prosper.

BPH Treatment Market News

• In June 2024, Olympus Corporation announced plans for an offshore R&D center in Hyderabad, India.
• In April 2024, Teleflex Incorporated announced the full market release of its UroLift 2 System integrated with the Advanced Tissue Control (ATC) feature for treating BPH in men with all types of prostates weight up to 100 grams, following FDA clearance.
• In April 2024, AbbVie Inc. began the construction of a new R&D building at its Ludwigshafen facility in Germany, aiming for operationalization in 2027. Christened LUdwighafens neue Arbeitswelt (LUnA), the building is being constructed with an investment of EUR 150 million.